Introduction
The thymus is required for de novo generation of naïve T cells with a broad T cell receptor repertoire 1 . Although thymic function in humans decreases after puberty, the adult thymus still contributes substantially to the restoration of immune competence after myeloablative therapy 2 . Factors that inhibit thymic function after allogeneic hematopoietic stem cell transplantation (alloHSCT) include thymic damage by the conditioning regimen 3, 4 as well as GvHD, where cell damage is mediated by donor alloreactive T cells 5, 6 . The consequence of delayed thymic recovery is profound T cell deficiency and repertoire restriction after alloHSCT 1, 7 . In consequence, the delay in thymic recovery is associated with a higher incidence of infections 8 and disease relapse 9 , furthermore it hinders success of immunotherapeutic strategies.
CD31 (PECAM-1) has been demonstrated to characterize the T cell receptor excision circles (TREC)-rich CD4 recent thymic emigrants (RTE) 10, 11 , and is already adopted into clinical practice as an excellent marker for thymic function in solid organ transplantation 12 and after autologous HSCT 13, 14 . Junge et al. (2007) could show a correlation between CD31+ CD4 T cells and the recurrence of TREC during aging of healthy individuals and in six lymphopenic children after alloHSCT 15 .
Rabbit antithymocyte globulin-Genzyme™ (ATG-G, Thymoglobulin®, Genzyme™
Transplant, Cambridge, MA, USA) therapy is commonly used for in vivo T cell depletion in the context of alloHSCT to prevent graft-versus-host disease (GvHD) 16 .
Different rabbit ATG preparations are currently available of which ATG-G and ATGFresenius™ (ATG-F, Fresenius™ Biotech GmbH, Munich, Germany) are frequently applied. ATG-F is manufactured by immunization of rabbits with a Jurkat cell line whereas ATG-G is manufactured by immunization of rabbits with human thymocytes.
In this study ATG-G was used, which contains a diverse spectrum of antibody specificities depleting various T cell subsets 17 . Clinical data regarding the effect of ATG-G on thymopoiesis after alloHSCT are scarce, and the effect of ATG-G on thymic output of regulatory CD4 T cells in particular after alloHSCT has not been studied yet.
The aim of this study was to assess the impact of ATG-G on the reconstitution of recent thymic emigrants (RTEs), naïve and memory T cell subsets of both conventional (Tcon) and regulatory (Treg) CD4 T cells in adult alloHSCT patients.
Suggesting a direct effect of ATG-G on the thymus, we also tested the ATG-G toxicity on human thymocytes in vitro and compared it to the effect of ATG-F as well as to the toxicity on peripheral blood mononuclear cells (PBMC). 
Design and Methods

Patients and treatment
Complement dependent cytotoxicity assay
Freshly isolated human thymocytes or PBMCs were resuspended at a density of 5x10 6 cells/ml in culture medium containing 2.5µg/ml, 25µg/ml or 100 µg/ml ATG-F or ATG-G respectively. 100 µl of each suspension was added to a round bottom microtiter plate and incubated for 60 min at 4°. After addition of 100 µl freshly prepared human serum the cells were incubated for 60 min at 37°C. Finally the samples were stained with propidium iodide solution and immediately analyzed by flow cytometry using a BD Fortessa flow cytometer (Becton Dickinson, Palo Alto, CA, USA) supported by FlowJo 9.3 software (TreeStar, Ashland, OR, USA).
Statistics and software
Calculations were performed in GraphPad Prism v5.0 (GraphPad Software, La Jolla, CA). Group comparisons were made with the Mann-Whitney-U test.
Results
ATG-G treatment impairs CD4 but not CD8 T cell recovery
Within the CD3 T cell compartment we analyzed the recovery of conventional CD4 T cells (Tcon, Figure 1A ) and regulatory CD4 T cells (Treg, Figure 1B ). In the ATG-G group the total peripheral Tcon and Treg cell counts were diminished by roughly 95% at day 15 after transplantation, and a significantly delayed recovery from day 30 to day 180 was observed compared to the patient cohort not treated with ATG-G. Mean
Tcon cell counts did not exceed 250 cells/µl at any time point after transplantation if treated with ATG-G, while mean Treg cell counts did not exceed 15 cells/µl. In contrast, there was no significant difference for the CD8 T cell recovery between the ATG-G treated versus non-treated cohort at any of the defined time points ( Figure   1C ).
T cell subset dependent recovery post alloHSCT
Next, we differentiated naïve (CD45RO-CD45RA+) and memory (CD45RO+CD45RA-) Tcon and Treg. The effect of ATG-G was most pronounced in the naïve subsets of both Tcon ( Figure 2A ) and Treg ( Figure 2B ). The naïve cell counts were significantly lower in the ATG-G group at all time points after transplantation as compared to the non-ATG-G group.
Memory CD4 Tcon ( Figure 2C ) and Treg ( Figure 2D ) were also more severely depleted in the ATG-G group than in the non-ATG-G group, but showed an overall more rapid recovery starting from day 30 after transplantation than the respective naïve subsets. Memory CD4 T cells were further differentiated into central memory (CM) CD4 T cells and effector memory (EM) CD4 T cells. CM CD4 T cells showed an almost complete depletion on day 15 in ATG-G treated patients. Their recovery was delayed until day 180 compared to the non-ATG-G group ( Figure 2E) . Levels of EM CD4 T cells were only significantly lower on day 15, and otherwise comparable in both groups ( Figure 2F ).
Impaired thymic generation of both naïve conventional and naïve FOXP3+ regulatory CD4+ T cells
Since the naïve cell subset in particular was depleted, we delineated the presence of RTE, in order to determine the thymic function and thymic output of CD4 T cells. We analyzed the recovery of the RTE CD4+ T cells based on the CD31 expression.
Representative gates of Tcon RTE and Treg RTE are shown in Figure 3A and 3B
respectively. In the ATG-G treated group a nearly complete lack of RTE of both Tcon and Treg cells was observed from day 15 until day 180. The Tcon RTE cell count initially decreased by 99.5% and its recovery did not start until day 180 ( Figure 3C ).
Similarly, Treg RTE cells were strongly depleted and remained stable at very low levels throughout day 180 in the ATG-G group ( Figure 3D ). In contrast, no significant decrease was observed in the non-ATG-G group.
Differential effects of ATG-G and ATG-F on human thymocytes and PBMCs in vitro
We hypothesized, that ATG-G might also have a strong cytotoxic effect on human thymocytes as ATG-G treated patients revealed significantly lower RTE counts and ATG-G is manufactured by immunization of rabbits with human thymocytes. We compared ATG-G with ATG-F, as ATG-F is manufactured by immunization of rabbits with Jurkat cells and not thymocytes. The in vitro cytotoxic effect of both ATGpreparations on cultured human thymocytes ( Figure 4A ) and PBMCs ( Figure 4B ) was studied at concentrations of 2.5µg/ml, 25µg/ml and 100µg/ml. In order to determine levels of necrosis and apoptosis, we co-stained for PI and AnnexinV. In order to investigate complement-mediated lysis as another important mechanism, we performed a complement-dependent cytotoxicity assay in accordance to Popow et al. 18 showing a dose-dependent specific lysis of thymocytes ( Figure 5A ) as well as PBMCs ( Figure 5B ) by both ATG types. ATG-G caused more complement-mediated lysis of thymocytes and PBMCs than ATG-F at the concentrations 25 and 100µg/ml, respectively.
Discussion
In our study, we analyzed the effect of ATG-G on thymic function and reconstitution of the T cell compartment, early after alloHSCT. Our initial findings demonstrated a significantly delayed recovery of total CD4 T cell counts in ATG-G treated patients, whereas total CD8 T cell counts were similar in ATG-G treated and non-treated patients. A number of studies found a more rapid recovery of CD8 than CD4 T cells in alloHSCT patients 19, 20 , and various factors as for example higher age and toxicity of the conditioning regimen have been associated with delayed CD4 T cell recovery [21] [22] [23] . A functional thymus has been shown to be necessary for the reconstitution of naïve CD4 T cells, whereas thymic-independent pathways seem to exist to regenerate naïve CD8 T cells 24 . Our study suggests, that ATG-G treatment is an additional factor that is associated with severe and prolonged thymic dysfunction after alloHSCT.
ATG-G treated patients exhibited a reconstitution failure of RTE of both Tcon and
Treg in peripheral blood, with hardly any recovery until day 180 after alloHSCT.
Regarding Tcon our results support previous findings of Sairafi et al., who reported
on reduced TREC levels in ATG-G treated patients in a retrospective study 25 .
Regarding Treg we found an impairment of thymic generation of Treg, which has not
been shown yet to our knowledge. Matsuoka et al. 26 have demonstrated abnormal
Treg homeostasis after alloHSCT in non-ATG-G treated patients with limited thymic generation of Treg and disturbed proliferative and apoptotic patterns. In this present study we could show, that ATG-G treatment is aggravating the imbalance by further limiting the thymic output. Normal Treg homeostasis may be crucial especially after alloHSCT, as Tregs regulate responses to allogeneic target antigens 27 and therefore are important in controlling GvHD [28] [29] [30] .
Results from in vitro studies 31, 32 and solid organ transplantation 33 suggest that ATG-G is capable of promoting Treg expansion thus contributing to GvHD prophylaxis. On the other hand, impaired thymic generation of Treg, as found in our study, may favor GvHD. Total body irradiation (TBI) is also known to negatively influence thymocyte viability 6 . A possible potentiation of irradiation and ATG-G effects cannot be excluded and might have additionally influenced RTE recovery in this study (Table   1 ).
In six days) to sub-therapeutic levels (<1µg/ml) by a median of 17 ± 9 days post transplantation at comparable treatment conditions 34 . They postulated that slow and prolonged T cell recovery was therefore not due to effects of ATG-G, assuming ATG-G activity only if present in therapeutic levels. However, in view of our results for Tcon RTE and Treg RTE recovery we suggest, that ATG-G also targets the thymus with long-term consequences for the thymic T cell recovery beyond week three after transplantation. ATG-G is prepared by immunizing rabbits with cells derived from the thymus organ, so that ATG-G should contain antibodies potentially targeting all cells, which are harbored within the thymus. The complex architecture of the human thymus is difficult to mimic in an experimental setup and it is thus not possible to determine in vitro concentrations of ATG that realistically reflect those concentrations of ATG that would be found within the thymus in vivo in the clinical situation of alloHSCT. Additionally, human thymic tissue is difficult to obtain, as it is hardly bioptically accessible. We thus decided to test different concentrations of ATG-G in a simplified experimental approach with fresh cultured human thymocytes. While induction of apoptosis by ATG-G in PBMCs has been shown previously 35 , our results show an apoptotic effect of ATG-G also on cultured human thymocytes.
Furthermore, thymocytes appear to be more susceptible to ATG-G induced cell death than PBMCs. As ATG-F is produced by immunization of rabbits against a
Jurkat cell line and not against human thymocytes, we also compared the effect of ATG-F and ATG-G on thymocytes. We could show a significantly stronger proapoptotic effect (late apoptosis) of ATG-G on thymocytes than ATG-F at 25µg/ml. In a recent study Popow et al. could show complement dependent lysis to be an important mechanism for ATG mediated cytotoxicity 18 . Our results suggest that complement dependent lysis is of equal importance in thymocyte toxicity of ATG-G. While recovery of naïve T cells was almost completely suppressed within in the first six months in ATG-G treated patients, memory T cell counts continuously increased, but were delayed compared to patients without ATG-G therapy. Looking at the memory compartment, our results suggest a preferential effect of ATG-G on CM CD4
T cells compared to EM CD4 T cells in the setting of alloHSCT. To our knowledge this has so far only been shown in solid organ transplantation 33, 38 . It has been suggested that CD4 memory T cells can cause a graft-versus-leukemia-(GvL-) effect without causing GvHD in mice 39 , a phenomenon that has more recently been ascribed to EM CD4 T cells in mouse models 40, 41 . From clinical studies on the other hand it is known that ATG-G contributes to prevention of GvHD without causing higher relapse rates in humans. The shift in the CD4 memory compartment after ATG-G treatment in favor of EM CD4 T cells in our study might thus be interpreted as an indication for one of the mechanisms underlying this mode of action of ATG-G.
Taken together, our findings suggest that ATG-G, which is raised against human thymocytes, may directly affect thymic cells and result in functional deficits. However, due to the rather small sample number, these data need to be confirmed in larger studies. In this respect, we suggest further comparative trials of different T-cell depleting approaches. Another possible consequence from our study is that thymusprotective and/or -supportive therapies such as keratinocyte growth factor, Interleukin 7, growth hormone and others -which are already discussed as treatment approaches to limit thymic damages by conditioning regimens (irradiation / chemotherapy) or GvHD -should be considered especially when ATG-G is used as GvHD prophylaxis. Differences in cell counts between ATG-G and non-ATG-G treated patients were statistically evaluated using the Mann Whitney test. * P < 0.05; ** P < 0.01; *** P < 0.005. Percentages of PI+ cells were tested in two independent experiments.
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